Your session is about to expire
← Back to Search
Pharmacogenomics
Pharmacogenetic-Guided Pain Management for Postoperative Pain (PRECISE Trial)
N/A
Waitlist Available
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Assigned female at birth and aged 18 years or older at the time of study initiation
Major gynecologic surgery indicated and planned for hysterectomy, myomectomy, exploratory laparotomy, and open abdominal surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights
PRECISE Trial Summary
This trial is looking at whether or not providing surgeons with information about a patient's genes and how they respond to drugs can help improve patient outcomes.
Who is the study for?
This trial is for individuals assigned female at birth, aged 18 or older, who are about to undergo major gynecologic surgery such as a hysterectomy. Participants must be willing to provide a cheek swab for genetic testing and follow study procedures. Pregnant or breastfeeding individuals, those on long-term opioid therapy, or if their physician advises against participation are excluded.Check my eligibility
What is being tested?
The study tests whether using pharmacogenetic testing (how genes affect drug response) can guide the choice of painkillers after surgery. It's a two-arm study where one group gets genotype-guided analgesic selection and the other receives usual care; both groups will have genetic testing done.See study design
What are the potential side effects?
Since this trial focuses on personalized medication choices based on genetics rather than new drugs, side effects would relate to individual responses to standard painkillers used post-surgery which could include nausea, constipation, dizziness, or allergic reactions.
PRECISE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I was assigned female at birth and am 18 or older.
Select...
I am scheduled for major surgery related to female reproductive organs.
PRECISE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility of integrating a PGx panel test in the EMR with a pharmacist consult note for each patient
Pharmacotherapy
Secondary outcome measures
Pain
Total opioid consumption in morphine milligram equivalents (MME)
PRECISE Trial Design
2Treatment groups
Experimental Treatment
Group I: Usual careExperimental Treatment2 Interventions
Pharmacogenetic testing using a 16 gene panel. Post-surgery analgesic selection will be based on usual care (not the PGx results). Pharmacist recommendations for all 16 gene results will be provided in a detailed note with a delayed return of results (30 days post surgery)
Group II: PGx-guidedExperimental Treatment3 Interventions
Pharmacogenetic testing using a 16 gene panel with a pharmacist consult providing genotype-guided recommendations for post-surgery analgesic selection based on CYP2D6 and CYP2C9 results. Pharmacist recommendations for all 16 gene results will also be provided in a detailed note.
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,879,976 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am willing to give a cheek swab for genetic testing and follow all study rules.I was assigned female at birth and am 18 or older.I have been on prescribed opioids for 3 months or more.My doctor advises against my participation in this trial.I am scheduled for major surgery related to female reproductive organs.
Research Study Groups:
This trial has the following groups:- Group 1: PGx-guided
- Group 2: Usual care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies available for prospective participants in this study?
"Unfortunately, this clinical trial is closed for recruitment. The first announcement was made on the 6th of October 2022 and the last update posted on September 19th 2022. That being said, there are still 590 other medical trials available to enrol in at present."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger